Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue 12, Pages 1176-1190
Publisher
Wiley
Online
2016-07-05
DOI
10.1111/dom.12735
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
- (2015) Lawrence Blonde et al. Cardiovascular Diabetology
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
- (2015) Jonatan Ising Bagger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Incretin-based therapies for obesity treatment
- (2015) Aline Haas de Mello et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
- (2015) Annachiara Uccellatore et al. Diabetes Therapy
- Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
- (2015) Annachiara Uccellatore et al. Diabetes Therapy
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Glucagon Regulates Hepatic Kisspeptin to Impair Insulin Secretion
- (2014) Woo-Jin Song et al. Cell Metabolism
- Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
- (2014) Jaimini Cegla et al. DIABETES
- Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
- (2014) Michaela Diamant et al. DIABETES CARE
- Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
- (2014) Helena M. de Wit et al. DIABETOLOGIA
- Metastasis Suppressor KISS1 Seems to Reverse the Warburg Effect by Enhancing Mitochondrial Biogenesis
- (2013) W. Liu et al. CANCER RESEARCH
- GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
- (2013) Daniel Lorber Cardiovascular Therapeutics
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
- (2013) K. M. Habegger et al. DIABETES
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
- Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
- (2012) T. M. Tan et al. DIABETES
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Unraveling oxyntomodulin, GLP1's enigmatic brother
- (2012) Alessandro Pocai JOURNAL OF ENDOCRINOLOGY
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study
- (2009) A. Elhayany et al. DIABETES OBESITY & METABOLISM
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started